PNT2258: Phase I data

Top-line data from Phase I trial in 22 patients showed that 1-150 mg/m 2 doses of PNT2258 were well tolerated, with an MTD of 150 mg/m 2 on days 1-5 of a 21-day cycle. Fatigue was the most common adverse event reported. DLTs included grade 3 increase in liver function tests and grade 4 thrombocytopenia. Data were presented at the AACR-NCI-EORTC International Symposium on Molecular Targets and Cancer Therapeutics in Dublin. ProNAi plans to start a Phase II trial evaluating 120 mg/m 2 PNT2258 given on days 1-5 of a 21 day cycle, but did not disclose a time frame. ...